Fig. 1 | Scientific Reports

Fig. 1

From: Automated and closed clinical-grade manufacturing protocol produces potent NK cells against neuroblastoma cells and AML blasts

Fig. 1

The workflow for the activated NK cell product in the CliniMACS prodigy. Manufacturing steps, sampling points and quality control (QC) analysis scheme are shown. Open phases are performed in the grade A isolator. *In the set-up phase, the sterility analysis was performed on leukapheresis sample directly. **Analyses designed to be performed for the products proceeding to clinical studies but not performed in this study. IPC in-process-control, NTCB-D non-target cell bag depletion, NTCB non-target cell bag, NC nucleocounter, RAB re-application bag, TCB target cell bag.

Back to article page